BH3 Profiling as a Companion Diagnostic For Velcade

对于多发性骨髓瘤的标准疗法和新疗法，显然需要更好地定义患者特异性治疗策略。Eutropics是唯一的定位，以提高多发性骨髓瘤的治疗效果，通过使用专有的分析，提供了一种新的预测性生物标志物，BH3分析。该分析独特地评估了癌细胞中的线粒体功能。这项技术在初步研究中被证明可以预测病人的病情

There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating multiple myeloma. Eutropics is uniquely positioned to improve therapy efficacy for multiple myeloma by using a proprietary assay that provides a novel predictive biomarker, BH3 profiling. The assay uniquely assesses mitochondrial functionality in cancer cells. This technology is proven in preliminary studies to predict the patient responsiveness to combination multiple myeloma therapies that induce apoptosis. Velcade/Bortezomib is one component of these therapeutic protocols. In this phase I contract Eutropics wi ll continue to develop the BH3 profiling assay to a state that can be transferred to a CliA 88 approved partner lab. Biopsied multiple myeloma patient samples will be obtained from academic/clinical advisors at Dana Farber Cancer Institute and profiled in Eutropics labs in Boston, MA, using our proprietary assay. Patient outcome data wi ll be correlated to the assay results. Eutropics will apply for the phase 2 study that will deliver the final standard operating protocols that will provide the Velcade companion diagnostic test. Discussions with manufacturer of Velcade are underway for possible collaboration.